265 related articles for article (PubMed ID: 22963187)
41. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
42. Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
Thai LP; Moss JR; Godman B; Vitry AI
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):419-33. PubMed ID: 26707482
[TBL] [Abstract][Full Text] [Related]
43. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
44. "Drugs to avoid" to improve quality use of medicines: how is Australia faring?
Vitry A; Mintzes B
J Pharm Policy Pract; 2021 Jul; 14(1):60. PubMed ID: 34256874
[TBL] [Abstract][Full Text] [Related]
45. Policy Updates on Access to and Affordability of Innovative Medicines in China.
Liu GG; Wu J; He X; Jiang Y
Value Health Reg Issues; 2022 Jul; 30():59-66. PubMed ID: 35235902
[TBL] [Abstract][Full Text] [Related]
46. "Price management" and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals.
Tordoff JM; Norris PT; Reith DM
Value Health; 2008 Dec; 11(7):1214-26. PubMed ID: 18489515
[TBL] [Abstract][Full Text] [Related]
47. Ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary.
Gauld R
Pharmacoeconomics; 2014 Oct; 32(10):937-42. PubMed ID: 24906479
[TBL] [Abstract][Full Text] [Related]
48. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
Ghosh D; Skinner M; Ferguson LR
Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
[TBL] [Abstract][Full Text] [Related]
49. Patients' Perspectives of the Pharmaceutical Regulatory and Reimbursement Systems in Istanbul, Turkey.
Mashaki Ceyhan E; Walker S; Salek S
Ther Innov Regul Sci; 2020 Sep; 54(5):1086-1096. PubMed ID: 32030691
[TBL] [Abstract][Full Text] [Related]
50. Provision of pharmaceuticals in Australian hospitals: equity of access?
Gallego G; Taylor SJ; Brien JA
Pharm World Sci; 2007 Apr; 29(2):47-50. PubMed ID: 17149650
[TBL] [Abstract][Full Text] [Related]
51. Availability of medicines in the European Union: results from the EURO-Medicines project.
Folino-Gallo P; Walley T; Frolich JC; Carvajal A; Edwards IR
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):441-6. PubMed ID: 11699607
[TBL] [Abstract][Full Text] [Related]
52. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
Morgan S; McMahon M; Greyson D
Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
[TBL] [Abstract][Full Text] [Related]
53. Widening consumer access to medicines through switching medicines to non-prescription: a six country comparison.
Gauld NJ; Kelly FS; Kurosawa N; Bryant LJ; Emmerton LM; Buetow SA
PLoS One; 2014; 9(9):e107726. PubMed ID: 25251434
[TBL] [Abstract][Full Text] [Related]
54. Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Aust N Z J Public Health; 2009 Jun; 33(3):246-52. PubMed ID: 19630844
[TBL] [Abstract][Full Text] [Related]
55. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
56. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
[TBL] [Abstract][Full Text] [Related]
57. Is higher population-level use of ICS/LABA combination associated with better asthma outcomes? Cross-sectional surveys of nationally representative populations in New Zealand and Australia.
Reddel HK; Beckert L; Moran A; Ingham T; Ampon RD; Peters MJ; Sawyer SM
Respirology; 2017 Nov; 22(8):1570-1578. PubMed ID: 28791752
[TBL] [Abstract][Full Text] [Related]
58. Will the Australia-United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?
Harvey KJ; Faunce TA; Lokuge B; Drahos P
Med J Aust; 2004 Sep; 181(5):256-9. PubMed ID: 15347273
[TBL] [Abstract][Full Text] [Related]
59. Straight talk with... Mark Sculpher. Interview by Kate Ravilious.
Sculpher M
Nat Med; 2012 Sep; 18(9):1315. PubMed ID: 22961148
[TBL] [Abstract][Full Text] [Related]
60. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?
Rawson NS
Clin Ther; 2003 Apr; 25(4):1230-47. PubMed ID: 12809970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
